SIMDAX® (i.v. levosimendan) is an inodilator (calcium sensitizer and potassium channel opener) indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.
If you are a healthcare professional, you can register as a user in the section for healthcare professionals for full information on SIMDAX®.
SIMDAX® is indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.
Our section for healthcare professionals provides additional and useful information, including several videos, on SIMDAX®. Join us and register HERE.
Yu L, Yuan K, Park BM, Kim SH
Eur J Pharmacol
Desai PM, Sarkar MS, Umbarkar SR
Ann Card Anaesth
Zhou S, Zhang L, Li J
Panchapakesan U, Pollock C
Putzu A, Clivio S, Belletti A, Cassina T
Int J Cardiol
Spartalis M, Tzatzaki E, Dimitroulis D, Spartalis E
1. Nieminen MS et al. Eur Heart J Suppl. 2017;19(suppl C);C15-C212. Papp Z et al. Int J Cardiol. 2012;159:82–87.
Next live event will take place on May 28th 2018 from the ESC-HF congress.Follow this page for updates on how to register etc.
Acute and Advanced Heart Failure Knowledge Center » Levosimendan in Wikipedia »Repetitive Levosimendan infusions for patients with advanced chronic heart failure »
Prof Pölzl's blog about therapeutic options for Acute and Advanced Heart Failure »
Heartfailurematters.org is an educational website available in 9 languages, developed by cardiologists, nurses, primary care physicians and patients from the Heart Failure Association of the ESC.
It highlights lifestyle adjustments that enable patients with heart failure to maintain their quality-of-life.
Visit Heart Failure Matters
Summary of Product Characteristics
This site is for professionals
of healthcare only.
Send us your